SYNTHESIS / FOUR FILES
Compare the Evidence, Not the Adjectives
Mechanism, model, endpoint, and replication reveal more than a shared “research peptide” label.
In plain English
These four compounds are not at the same stage. NAD+ precursor studies in people reliably move a blood marker, but broad anti-ageing benefit remains unproven [1][2][5]. GHK-Cu has a limited topical human record plus extensive laboratory and review-based claims [8][9][11]. Retatrutide has randomized Phase 2 human trials with large metabolic changes, yet it remains investigational and lacks mature long-term outcomes [13][15][16][17]. KPV has no published human efficacy trial in this corpus; its anti-inflammatory case comes from cells and mice [18][20][21].
A fair comparison does not ask which compound sounds strongest. It asks what was tested, in which model, against what control, and with what endpoint. The same word—“promising”—can describe a replicated biomarker, a small topical signal, a mid-stage drug trial, or an animal mechanism. Those are materially different claims.
The evidence ledger
| Compound | Primary mechanism | Strongest evidence in this corpus | What is not established |
|---|---|---|---|
| NAD+ | Redox carrier and substrate for sirtuins, PARPs, and CD38 | Controlled human precursor trials consistently raise blood NAD+ [2][5] | Longevity, disease prevention, and consistent tissue-level benefit [1] |
| GHK-Cu | Copper coordination plus signaling tied to matrix and repair pathways | Limited topical human work, ex vivo penetration, and mechanistic reviews [8][11][12] | Broad systemic regeneration or validated injectable use |
| Retatrutide | Agonism at GIP, GLP-1, and glucagon receptors | Randomized Phase 2 human metabolic trials [15][16][17] | Approval, long-term outcomes, rare harms, and durable off-treatment effect [13] |
| KPV | PepT1 uptake with suppression of inflammatory signaling | Cell work and multiple mouse colitis or delivery studies [18][19][20][21] | Human efficacy, pharmacokinetics, and safety |
Mechanism is a map, not a destination
Mechanistic confidence differs from clinical confidence. NAD+ biology is fundamental: cells require it, and its enzyme network is well described [4]. That makes the pathway important but does not specify whether supplementation changes a meaningful human outcome. GHK-Cu has an unusually broad mechanistic narrative spanning matrix production and gene expression [9][11]. The breadth increases the number of hypotheses; it does not multiply the number of controlled human trials.
Retatrutide offers the cleanest match between designed mechanism and observed human outcome. Structural work confirms engagement at all three intended receptors [14], while Phase 2 trials report large changes in metabolic endpoints [15][16][17]. Even here, mechanism cannot supply missing years of safety follow-up. KPV shows the opposite pattern: transport and inflammatory signaling are coherent, and animal studies repeat related effects [20][21], but the chain stops before human testing.
Endpoints decide what the result means
NAD+ precursor trials often begin with circulating NAD+ as the endpoint. That answers whether the precursor changes a measurable pool, not whether ageing slows [1][2][5]. GHK-Cu research moves among penetration, gene expression, collagen-related measures, cosmetic appearance, and hair counts [8][9][10][12]. Each endpoint needs its own conclusion, especially when a hair formulation contains more than one active component [10].
Retatrutide trials examine body weight, glucose control, liver fat, adverse events, and heart rate [15][16][17]. Those outcomes are closer to direct clinical relevance, but some remain surrogate or intermediate measures. KPV studies examine inflammatory signaling, tissue damage, cytokines, and recovery in induced mouse colitis [18][19][20][21]. They are useful for deciding whether human research is justified. They are not estimates of human treatment effect.
What would change the ranking
For NAD+, larger and longer human trials would need tissue measurements and outcomes that matter beyond blood chemistry. For GHK-Cu, independent controlled trials of defined topical formulations would need to separate the peptide from co-ingredients and delivery procedures. For retatrutide, Phase 3 replication, mature safety surveillance, and completed cardiovascular or renal outcome work would determine whether the large mid-stage signal holds. For KPV, a characterized formulation would first need credible human pharmacology and early clinical safety before efficacy claims could be weighed.
This is why the comparison is intentionally dated rather than final. Evidence maturity can change quickly, but it only changes when new data answer the missing question. A press release, a new mechanism diagram, or a larger volume of anecdote does not move the same boundary.
A disciplined reading order
Begin with study design, then read the number. Check species and population. Separate the tested formulation from the named molecule. Ask whether the source is a primary experiment or a review, and whether independent work reaches a similar conclusion. Finally, match the claim to the endpoint actually measured.
Applied consistently, that order prevents two common errors: dismissing all early research because it is early, and treating all positive research as ready for human use. KPV can be a credible preclinical program without being a human therapy. Retatrutide can show unusually large Phase 2 effects without being approved. NAD+ can be essential biology without being a proven longevity intervention. GHK-Cu can have topical promise without validating systemic repair. Precision is less dramatic than promotion and more useful.